Genetic Analysis of Signaling Components in Innate Immunity

先天免疫信号成分的遗传分析

基本信息

  • 批准号:
    7670122
  • 负责人:
  • 金额:
    $ 23.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

Type I interferon (IFN) provides an initial component of innate immune resistance to viral infection and replication by inducing a large set of antiviral effector proteins capable of inhibiting diverse viruses at multiple points in the infection. Inherent to the effectiveness of this response are cellular signaling pathways that first trigger IFN gene induction in response to infection and subsequently trigger IFN-stimulated gene (ISG) expression in response to secreted IFN. IFN gene induction proceeds through two distinct pathways, a cytosolic signaling system triggered by viral nucleic acid in the cytoplasm that operates in most infected cells and a transmembrane pathway dependent on Toll-like receptor (TLR) proteins that is critical in dendritic cells. The essential nature of the IFN system in antiviral immunity has been demonstrated by genetic and biochemical data, but its ultimate effectiveness is limited by viral evasion through the action of viral virulence factors that impaire IFN action. The underlying hypothesis of our proposed research is that through better understaning the molecular mechanisms of IFN induction and action and their impairment by viral evasion, we will be able to devise novel therapeutics based on augmenting innate immunity and inhibiting viral evasion. This project focuses on three distinct viruses that each impair the IFN pathway, influenza A virus, vaccinia virus, and chikungunya virus; will analyze the interaction between viruses and IFN signaling in a unique set of genetically modified dendritic cells lines; and will develop a platform to screen for small molecule inhibitors of viral virulence. This work will be performed in close collaboration with other members of the innate immunity team, Drs. Easier, Garcia-Sastre, and Wu. This project is well integrated into the mission of the RCE. Innate immunity has emerged as an essential component of the key focus areas of the RCE, impacting on adaptive immunity and being critical for athe adjuvant effects of vaccines; providing an important diagnostic indication of infection; and uncovering a novel approach to therapeutics by targeting the interaction between the innate immune system and virulence factors. Knowledge gained in these studies will also be applicable to microbial innate immunity that relies on similar mechani
I型干扰素提供对病毒感染和复制的先天免疫抵抗的初始成分 通过诱导大量的抗病毒效应蛋白能够在体内的多个点抑制不同的病毒 感染。这种反应的有效性所固有的是首先触发干扰素基因的细胞信号通路 诱导对感染的应答并随后触发干扰素刺激基因(ISG)的表达 分泌型干扰素。干扰素基因的诱导通过两条不同的途径进行,胞质信号系统由 在大多数感染细胞中运行的细胞质中的病毒核酸和依赖于 在树突状细胞中起关键作用的Toll样受体(TLR)蛋白。干扰素系统在抗病毒中的本质 免疫力已被遗传和生化数据证明,但其最终效果受到病毒的限制。 通过削弱干扰素作用的病毒毒力因子的作用而逃避。我们提出的基本假设是 研究表明,通过更好地了解干扰素的诱导和作用的分子机制以及它们的 通过病毒逃避造成的损害,我们将能够设计出基于增强先天免疫和 抑制病毒逃避。该项目重点关注三种不同的病毒,每种病毒都会破坏干扰素途径,即甲型流感 病毒、牛痘病毒和基孔肯雅病毒;将分析病毒之间的相互作用和干扰素信号在一个独特的 一套转基因树突状细胞系;并将开发一个筛选病毒小分子抑制剂的平台 致命性。这项工作将与先天免疫团队的其他成员密切合作进行。 更容易,加西亚-萨斯特,还有吴。 该项目很好地融入了区域经济委员会的使命。先天免疫力已经成为一种必不可少的 RCE关键焦点区域的组成部分,影响获得性免疫,对佐剂至关重要 疫苗的效果;提供感染的重要诊断指征;以及揭示一种新的方法 通过靶向天然免疫系统和毒力因子之间的相互作用进行治疗。学到的知识 这些研究也将适用于依赖类似机制的微生物先天免疫。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David E Levy其他文献

RIGging an antiviral defense—it's in the CARDs
操纵抗病毒防御——这在 CARD 中。
  • DOI:
    10.1038/ni0704-699
  • 发表时间:
    2004-07-01
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    David E Levy;Isabelle J Marié
  • 通讯作者:
    Isabelle J Marié

David E Levy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David E Levy', 18)}}的其他基金

A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
基孔肯雅病毒复制子作为抗病毒治疗的平台
  • 批准号:
    8789899
  • 财政年份:
    2014
  • 资助金额:
    $ 23.94万
  • 项目类别:
Acquisition of an X-Rad 320 Biological Irradiator
购买 X-Rad 320 生物辐照器
  • 批准号:
    8703903
  • 财政年份:
    2014
  • 资助金额:
    $ 23.94万
  • 项目类别:
Training Program in Molecular Oncology and Immunology
分子肿瘤学和免疫学培训计划
  • 批准号:
    8761272
  • 财政年份:
    2013
  • 资助金额:
    $ 23.94万
  • 项目类别:
A chikungunya Viral Replicon as a Platform for Antiviral Therapeutics
基孔肯雅病毒复制子作为抗病毒治疗的平台
  • 批准号:
    8302538
  • 财政年份:
    2011
  • 资助金额:
    $ 23.94万
  • 项目类别:
LUNG INTERFERON IN INFLUENZA VIRUS INFECTION
肺干扰素在流感病毒感染中的作用
  • 批准号:
    6610320
  • 财政年份:
    2002
  • 资助金额:
    $ 23.94万
  • 项目类别:
NPM ALK mediated transformation of T lymphocytes
NPM ALK 介导的 T 淋巴细胞转化
  • 批准号:
    6991316
  • 财政年份:
    2001
  • 资助金额:
    $ 23.94万
  • 项目类别:
LUNG INTERFERON IN INFLUENZA VIRUS INFECTION
肺干扰素在流感病毒感染中的作用
  • 批准号:
    6480396
  • 财政年份:
    2001
  • 资助金额:
    $ 23.94万
  • 项目类别:
NPM ALK mediated transformation of T lymphocytes
NPM ALK 介导的 T 淋巴细胞转化
  • 批准号:
    7197729
  • 财政年份:
    2001
  • 资助金额:
    $ 23.94万
  • 项目类别:
FUNCTION OF IRF7 IN RESPONSE TO VIRUS INFECTION
IRF7 应对病毒感染的功能
  • 批准号:
    6196084
  • 财政年份:
    2000
  • 资助金额:
    $ 23.94万
  • 项目类别:
FUNCTION OF IRF7 IN RESPONSE TO VIRUS INFECTION
IRF7 应对病毒感染的功能
  • 批准号:
    6374366
  • 财政年份:
    2000
  • 资助金额:
    $ 23.94万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 23.94万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 23.94万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 23.94万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 23.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 23.94万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 23.94万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 23.94万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 23.94万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 23.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 23.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了